AGA临床实践更新:胰腺坏死管理
美国胃肠病协会(AGA)发布胰腺坏死管理临床实践更新,提出15条最佳实践建议。内容涵盖多学科管理、抗菌药物使用、营养支持、引流与清创时机、内镜与微创手术选择等,强调阶梯式治疗策略。
要点
- 胰腺坏死管理需多学科协作,重症患者考虑转诊至三级中心。
- 抗菌药物仅用于确诊或高度怀疑感染,不推荐预防性使用。
- 有感染或症状性坏死时需引流/清创,早期(前2周)避免清创,最佳延迟至4周。
核心结论
- 胰腺坏死管理应采用多学科协作和阶梯式治疗策略,根据病情选择引流或清创。
研究设计与样本
- 由AGA临床实践更新委员会委托并批准的专家综述,基于文献和专家经验提出15条最佳实践建议。
主要发现
- 胰腺坏死与显著 morbidity 和 mortality 相关,优化管理需要多学科团队。
- 预防性抗生素不推荐用于无菌坏死,怀疑感染时选用能穿透胰腺坏死的广谱静脉抗生素。
- 早期肠内喂养可降低感染坏死风险,口服耐受时优先口服,否则尽快管饲。
- 清创应避免在急性期前2周进行,最佳延迟至4周。
- 对于包裹性坏死(WON),经皮引流和透壁内镜引流均为一线非手术方法,内镜引流可能更优。
关键数值与推荐
- 抗菌治疗指征:培养证实感染或高度怀疑感染(如集合内气体、菌血症、脓毒症或临床恶化)。
- 引流/清创指征:感染坏死;或无菌坏死但持续不适(腹痛、恶心、呕吐、营养失败)或相关并发症(胃肠道梗阻、胆道梗阻、复发性急性胰腺炎、瘘、持续SIRS)。
- 清创时机:避免前2周,最佳延迟4周,仅在有明确指征和包裹性集合时提前。
- 营养支持:无恶心呕吐和严重肠梗阻时立即尝试口服,否则尽快鼻胃/十二指肠或鼻空肠管饲,全肠外营养仅在其他途径不可行时考虑。
- 内镜引流:自膨式金属支架(如LAMS)优于塑料支架;直接内镜坏死清除术限于坏死有限且引流反应不佳者,或大量感染坏死,需在转诊中心进行。
临床怎么用
- 临床怀疑感染坏死时,使用能穿透胰腺坏死的广谱静脉抗生素,不常规用抗真菌药。
- 尽早启动肠内营养,口服优先,不能口服时尽快管饲。
- 有指征时选择阶梯式策略:经皮或内镜引流,必要时内镜坏死清除术,最后手术清创。
- 胰腺坏死患者应有多学科团队管理,复杂病例转诊至三级中心。
局限性
- 本更新为专家综述,基于现有证据和专家经验,非系统评价。
- 部分建议缺乏高级别证据支持,如断离左胰残端的长期内镜支架治疗证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and expert recommendations regarding the clinical care of patients with pancreatic necrosis and to offer concise best practice advice for the optimal management of patients with this highly morbid condition. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. This review is framed around the 15 best practice advice points agreed upon by the authors, which reflect landmark and recent published articles in this field. This expert review also reflects the experiences of the authors, who are advanced endoscopists or hepatopancreatobiliary surgeons with extensive experience in managing and teaching others to care for patients with pancreatic necrosis. BEST PRACTICE ADVICE 1: Pancreatic necrosis is associated with substantial morbidity and mortality and optimal management requires a multidisciplinary approach, including gastroenterologists, surgeons, interventional radiologists, and specialists in critical care medicine, infectious disease, and nutrition. In situations where clinical expertise may be limited, consideration should be given to transferring patients with significant pancreatic necrosis to an appropriate tertiary-care center. BEST PRACTICE ADVICE 2: Antimicrobial therapy is best indicated for culture-proven infection in pancreatic necrosis or when infection is strongly suspected (ie, gas in the collection, bacteremia, sepsis, or clinical deterioration). Routine use of prophylactic antibiotics to prevent infection of sterile necrosis is not recommended. BEST PRACTICE ADVICE 3: When infected necrosis is suspected, broad-spectrum intravenous antibiotics with ability to penetrate pancreatic necrosis should be favored (eg, carbapenems, quinolones, and metronidazole). Routine use of antifungal agents is not recommended. Computed tomography-guided fine-needle aspiration for Gram stain and cultures is unnecessary in the majority of cases. BEST PRACTICE ADVICE 4: In patients with pancreatic necrosis, enteral feeding should be initiated early to decrease the risk of infected necrosis. A trial of oral nutrition is recommended immediately in patients in whom there is absence of nausea and vomiting and no signs of severe ileus or gastrointestinal luminal obstruction. When oral nutrition is not feasible, enteral nutrition by either nasogastric/duodenal or nasojejunal tube should be initiated as soon as possible. Total parenteral nutrition should be considered only in cases where oral or enteral feeds are not feasible or tolerated. BEST PRACTICE ADVICE 5: Drainage and/or debridement of pancreatic necrosis is indicated in patients with infected necrosis. Drainage and/or debridement may be required in patients with sterile pancreatic necrosis and persistent unwellness marked by abdominal pain, nausea, vomiting, and nutritional failure or with associated complications, including gastrointestinal luminal obstruction; biliary obstruction; recurrent acute pancreatitis; fistulas; or persistent systemic inflammatory response syndrome. BEST PRACTICE ADVICE 6: Pancreatic debridement should be avoided in the early, acute period (first 2 weeks), as it has been associated with increased morbidity and mortality. Debridement should be optimally delayed for 4 weeks and performed earlier only when there is an organized collection and a strong indication. BEST PRACTICE ADVICE 7: Percutaneous drainage and transmural endoscopic drainage are both appropriate first-line, nonsurgical approaches in managing patients with walled-off pancreatic necrosis (WON). Endoscopic therapy through transmural drainage of WON may be preferred, as it avoids the risk of forming a pancreatocutaneous fistula. BEST PRACTICE ADVICE 8: Percutaneous drainage of pancreatic necrosis should be considered in patients with infected or symptomatic necrotic collections in the early, acute period (<2 weeks), and in those with WON who are too ill to undergo endoscopic or surgical intervention. Percutaneous drainage should be strongly considered as an adjunct to endoscopic drainage for WON with deep extension into the paracolic gutters and pelvis or for salvage therapy after endoscopic or surgical debridement with residual necrosis burden. BEST PRACTICE ADVICE 9: Self-expanding metal stents in the form of lumen-apposing metal stents appear to be superior to plastic stents for endoscopic transmural drainage of necrosis. BEST PRACTICE ADVICE 10: The use of direct endoscopic necrosectomy should be reserved for those patients with limited necrosis who do not adequately respond to endoscopic transmural drainage using large-bore, self-expanding metal stents/lumen-apposing metal stents alone or plastic stents combined with irrigation. Direct endoscopic necrosectomy is a therapeutic option in patients with large amounts of infected necrosis, but should be performed at referral centers with the necessary endoscopic expertise and interventional radiology and surgical backup. BEST PRACTICE ADVICE 11: Minimally invasive operative approaches to the debridement of acute necrotizing pancreatitis are preferred to open surgical necrosectomy when possible, given lower morbidity. BEST PRACTICE ADVICE 12: Multiple minimally invasive surgical techniques are feasible and effective, including videoscopic-assisted retroperitoneal debridement, laparoscopic transgastric debridement, and open transgastric debridement. Selection of approach is best determined by pattern of disease, physiology of the patient, experience and expertise of the multidisciplinary team, and available resources. BEST PRACTICE ADVICE 13: Open operative debridement maintains a role in the modern management of acute necrotizing pancreatitis in cases not amenable to less invasive endoscopic and/or surgical procedures. BEST PRACTICE ADVICE 14: For patients with disconnected left pancreatic remnant after acute necrotizing mid-body necrosis, definitive surgical management with distal pancreatectomy should be undertaken in patients with reasonable operative candidacy. Insufficient evidence exists to support the management of the disconnected left pancreatic remnant with long-term transenteric endoscopic stenting. BEST PRACTICE ADVICE 15: A step-up approach consisting of percutaneous drainage or endoscopic transmural drainage using either plastic stents and irrigation or self-expanding metal stents/lumen-apposing metal stents alone, followed by direct endoscopic necrosectomy, and then surgical debridement is reasonable, although approaches may vary based on the available clinical expertise.
引用
- Baron TH, DiMaio CJ, Wang AY, et al. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2019. PMID: 31479658. doi:10.1053/j.gastro.2019.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。